Live by the EpiPen, die by the EpiPen
Zach Shallbetter

What’s the beef with Daraprim? A competitor released a similar drug for around $1 within a week of Daraprim’s price-hike.

Also, why isn’t PATENT-REFORM ever mentioned here? The injector for Epinephrine is still under patent. Countries that don’t have to respect our patent laws still sell this product for a fraction of what it costs here.

Show your support

Clapping shows how much you appreciated Dan Orlovsky’s story.